ARTICLE | Company News

Final approval for Stavzor

July 31, 2008 1:57 AM UTC

FDA granted final approval for an NDA for Stavzor valproic acid from Banner (High Point, N.C.) and Noven (NASDAQ:NOVN) to treat manic episodes associated with bipolar disorder and to prevent migraines. In December, FDA granted tentative approval pending the July 29 expiration of exclusivity for Depakote divalproex from Abbott (NYSE:ABT). ...